Posted by Michael Wonder on 10 Oct 2025
US FDA approves Boehringer’s Jascayd (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
9 October 2025 - Approval is based on results from two clinical trials, which showed reduction in forced vital capacity decline with Jascayd versus placebo in adults with idiopathic pulmonary fibrosis.
Boehringer Ingelheim’s Jascayd (nerandomilast) tablets has been approved by the US FDA as an oral treatment option for idiopathic pulmonary fibrosis in adult patients.
